Tango Therapeutics, Inc.TNGXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +8.15% | -24.19% | -16.67% | -83.99% | +363.61% |
| Gross Profit Growth | +14.71% | -24.19% | -16.67% | -87.14% | +358.83% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +11.82% | +13.45% | +1.97% | +2.06% | +2.27% |
| Weighted Average Shares Diluted Growth | +11.82% | +13.45% | +1.97% | +2.06% | +2.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -17.70% | -21.38% | -32.47% | -37.64% | -40.37% |
| Book Value per Share Growth | -25.91% | -30.52% | -38.16% | -46.61% | -31.72% |
| Debt Growth | -4.76% | -6.24% | -3.37% | -7.48% | -7.61% |
| R&D Expense Growth | +22.52% | +8.29% | -4.26% | -16.74% | -9.03% |
| SG&A Expenses Growth | +30.55% | +21.80% | +7.68% | +5.27% | -20.48% |